Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $42,651 | $36,757 |
| General and administrative | 11,464 | 9,202 |
| Total operating expenses | 54,115 | 45,959 |
| Loss from operations | (54,115) | (45,959) |
| Other income | ||
| Interest income | 5,102 | 5,161 |
| Total other income | 5,102 | 5,161 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s R&D?
- Edgewise Therapeutics, Inc. (EWTX) reported R&D of $42.65M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s R&D changed year-over-year?
- Edgewise Therapeutics, Inc.'s R&D increased by 16.0% year-over-year, from $36.76M to $42.65M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s R&D has grown at a 47.3% compound annual growth rate (CAGR), from $32.19M to $151.39M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Edgewise Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude